伯氏疟原虫Pb22截短蛋白免疫血清的传播阻断能力的研究

为探讨伯氏疟原虫(Plasmodium berghei)Pb22蛋白免疫血清的传播阻断能力,应用原核表达系统高效表达Pb22截短蛋白免疫小鼠后获得免疫血清。IFA实验证明Pb22截短蛋白免疫血清均可与疟原虫天然抗原结合。通过传播阻断实验,比较了Pb22截短蛋白和全长蛋白免疫血清的传播阻断效果,证明截短蛋白和全长蛋白对雄配子体出丝均有抑制作用,结果表明全长蛋白免疫小鼠的雄配子体出丝与对照组相比显著下降,截短蛋白免疫小鼠的雄性配子体出丝具有下降趋势但无统计学差异。全长蛋白和截短蛋白免疫小鼠的动合子形成数量较对照组均显著下降。以上结果表明抗Pb22截短蛋白免疫血清具有传播阻断能力,但阻断效果不如全长蛋白免疫血清。     

间日疟原虫传播阻断疫苗研究新进展

间日疟原虫是导致人类感染疟疾的4种疟原虫之一。由于间日疟具有较强的遗传多样性和更易复发等特点,间日疟原虫的防治得到人们的日益关注,其中疫苗的研发是重要的防控手段,传播阻断疫苗作为可以阻断传播的疫苗,相关方面的研究却刚刚起步。综述了间日疟传播阻断疫苗研究方面的新进展,旨在为间日疟疫苗的研制提供参考。     

新型疟疾传播阻断疫苗候选抗原PbPSOP7基因截短片段的克隆及表达特点的研究

传播阻断疫苗(transmission-blocking vaccines,TBVs)可以有效地阻断疟原虫从蚊媒向人的传播,是控制疟疾流行的关键,但目前的TBVs候选抗原十分有限,迫切需要寻找有效的候选抗原。动合子分泌蛋白7(putative secreted ookinete protein 7,PSOP7)在疟原虫有性生殖阶段发挥着至关重要的作用,本研究对伯氏疟原虫抗原PSOP7(Pb PSOP7)进行简要的生物信息学分析,并应用原核表达系统高效表达纯化了截短的重组Pb PSOP7蛋白(r Pb PSOP7),免疫BALB/c小鼠后,获得小鼠高滴度多克隆抗体。经Western Blot方法证实该多克隆抗体可识别疟原虫抗原。间接免疫荧光实验显示,Pb PSOP7主要表达于疟原虫的合子与动合子表面。这些特点符合TBVs的基本设计理念,为确认和证实Pb PSOP7蛋白具有疟疾TBVs候选抗原的潜能奠定基础。     

约氏疟原虫Pys48核酸疫苗传播阻断效应的实验研究

探讨约氏疟原虫（Plasmodium yoelii17XL）Pys48核酸疫苗免疫BALB/c小鼠的特异性抗体产生特点及其效应。将Pys48核酸疫苗肌肉内注射免疫BALB/c小鼠,并以空质粒注射组作为对照,3次免疫后通过P.y17XL攻击小鼠;采用ELISA检测免疫后小鼠血清中特异性抗体水平;通过P.y17XL感染小鼠,取其感染后第3天含有配子体的血液进行体外培养,观察合子、动合子的形成数量。ELISA结果显示疫苗免疫组小鼠血清特异性抗体滴度明显高于对照组;而合子、动合子数量明显低于对照组。提示Pys48核酸疫苗具有良好的免疫原性,免疫小鼠后可以建立起有效的传播阻断效应。     

传播阻断型疟疾疫苗的研究进展

由于抗药疟原虫和蚊虫的出现,给疟疾防治带来了困难。研发安全有效的疟疾疫苗是当前全球疟疾防治的迫切需求。目前,正在研究的疟疾疫苗主要包括红前期疟疾疫苗、红内期疟疾疫苗和传播阻断型疟疾疫苗。其中传播阻断型疫苗(Transmission-blocking vaccines,TBVs)被认为是一种在疟疾流行地区降低病原体传播的可行策略。近年来,传播阻断型疟疾疫苗的研制取得了很大的进展。本文综述了传播阻断型疟疾疫苗的用途、靶抗原以及传播阻断型恶性疟疾和间日疟疾疫苗研究现状,旨在为传播阻断型疟疾疫苗的研制提供参考。     

重组恶性疟原虫DNA质粒免疫小鼠制备单克隆抗体

用恶性疟原虫MSP131基因片段的重组质粒DNA直接免疫BALB/c小鼠,诱导产生体液,免疫后取脾细胞与SP2/0小鼠骨髓瘤细胞在PEG1450作用下进行融合,获得了2株能分泌抗恶性疟原虫MSP131单克隆抗体的小鼠杂交瘤细胞株9H9和8A2。用酶联免疫吸附试验检测,小鼠腹水抗体滴度最高为1∶10 000。经免疫球蛋白类型和亚类鉴定,2株杂交瘤细胞株均为IgG\-1\.蛋白免疫印迹试验表明,此单克隆抗体与MSP1\|31蛋白抗原有特异免疫反应,证明通过质粒DNA直接免疫小鼠可制备特异性单克隆抗体。     

传播阻断型恶性疟疾疫苗的研究进展

迄今为止,恶性疟疾仍然是严重威胁人类健康的传染性疾病之一.由于抗药性疟原虫的出现,研究安全、有效且廉价的恶性疟疾疫苗迫在眉睫.综述了当前在研究中的3种恶性疟疾疫苗,并从候选抗原性质、当前研究中的问题和抗原免疫原性等方面重点介绍了传播阻断型恶性疟疾疫苗的现状,为传播阻断型疟疾疫苗的研发提供了参考.     

伯氏疟原虫氯喹敏感株和抗性株感染红细胞精脒合成酶体内观察

给伯氏疟原虫氯喹敏感株(CS)和抗氯喹株(CR)感染鼠腹腔注入~3H-丁二胺(0.74MB_q/鼠),4h后用荧光法与液闪法测定CS、CR感染RBC中产生的~3H-精脒量,以示精脒合成酶的活力(以dpra/10~9感染RBC表示),并观察了氯喹对酶活力的影响。两株感染RBC的酶活力在治疗前接近,CS为59 987.9±17403(16),CR为53818.4±15565(13)。氯喹治疗20h后CS与CR分别为20033±3260(8)与65304±20176(11)即CS酶活力降低66.6％,CR的活力不变,推测氯喹对两株疟原虫感染RBC精脒抑制的差异点是在精眯合成酶环节。     

约氏疟原虫与伯氏疟原虫诱导感染小鼠产生保护性抗体的特点研究

比较约氏疟原虫(Plasmodium yoelii)与伯氏疟原虫(Plasmodium berghei)再次感染模型特异性抗体产生的差异,追溯相应虫体抗原的表达特点.建立约氏疟原虫与伯氏疟原虫再次感染鼠疟模型,ELISA检测特异性抗体水平;Western Blot检测血清中优势抗体反应特点;检测两种虫株的MSP-1重组...     

乙型肝炎疫苗和乙型肝炎母婴传播的免疫阻断

乙型肝炎疫苗和高价抗乙肝免疫球蛋白(HBIG)均已研制成功,并开始大量生产使用,这是近年预防医学和生物制品研究的两项重大突破;它使人类在征服全球性重大传染病方面又迈出了历史性的一步。近十年来的研究已完全确认,上述两大制品在预防高危人群乙肝感染和阻断暴露后人群(如乙肝带毒母亲的婴儿)的乙肝带毒,卓有成效。这两大生物制品的有计划大量生产和正确使用,将会根本改变乙肝的流行状况,使控制和甚至消灭乙肝成为可能。现就国内外乙肝疫苗,高价乙肝免疫球蛋白的研究、生产和应用现状及乙肝母婴传播的免疫阻断等有关问题,作一简要介绍。     

Plasmodium berghei K173: Selection of resistance to naphthoquine in a mouse model

Naphthoquine (NQ), as a component of ARCO® which composed of NQ and artemisinin, is a new 4-aminoquinoline antimalarial synthesized by our institute. Here, a naphthoquine-resistant line of rodent malaria parasite was selected through exposing Plasmodium berghei Keyberg 173 strain to progressively increased drug pressure. The selected strain showed a more than 200-fold decreased susceptibility to NQ with a stable resistance phenotype after 10 serial passages without drug pressure or when cryopreserved over a period of 12 months. In a cross-resistance assay, the susceptibility of NQ-resistant parasites to chloroquine was decreased by 14.5-fold. These findings imply NQ-resistant parasites might be selected by long-term usage of NQ in epidemic areas and the efficacy of NQ or ARCO® in chloroquine-resistant Plasmodium falciparum epidemic areas should be monitored closely.     

茄科劳尔氏菌单克隆抗体的制备及其特性鉴定

茄科劳尔氏菌(Ralstonia solanacearum,RS)是番茄、茄子、辣椒、马铃薯等茄科蔬菜青枯病害的致病菌。为实现对RS的快速高效检测,以茄科劳尔氏菌株1.76免疫BALB/c小鼠,经细胞融合后利用间接酶联免疫吸附分析(Enzyme-linked Immunosorbent Assay,ELISA)筛选出3株能稳定分泌抗茄科劳尔氏菌株1.76的单克隆杂交瘤细胞株1C1、1B3和9D7。然后利用小鼠体内诱生腹水,1C1、1B3和9D7效价分别为1:1 024 000、1:64 000、1:256 000。采用饱和硫酸铵沉淀及Protein-G亲和层析法纯化腹水,经SDS-PAGE鉴定显示纯化后的单克隆抗体(Monoclonal Antibodies,mAb)纯度较高。纯化后单克隆抗体(2 mg/mL)效价分别为1:17 529、1:35 819、1:50 000,抗体亚型均为IgG1。对3株抗体进行特异性检测结果显示,1C1和9D7均不能与RS-5结合,1B3不能结合1.74和RS-5。此外,检测结果还表明3株单克隆抗体与桑肠杆菌JX-6、苏云金芽胞杆菌SYJ及实验室现有11株燕麦嗜酸菌卡特莱兰亚种、燕麦嗜酸菌西瓜亚种、玉米细菌性条斑菌、嗜酸菌魔芋亚种,梨火疫病菌QB0809、 XL-4,玉米细菌性枯萎病菌QB0241、QB0242,水稻细菌性谷枯病菌QB0017、QB0753、QB0755均无交叉情况。此次茄科劳尔氏菌抗体的制备,为后期青枯病菌的快速检测提供参考。     

PD-1对伯氏疟原虫感染小鼠体液免疫应答的影响

利用伯氏疟原虫Plasmodium berghei ANKA(P.b ANKA)感染BALB/c小鼠,PD-1单抗阻断后,流式细胞术检测脾脏浆细胞、滤泡辅助性T细胞(Tfh)数量。qRT-PCR检测IL-21、IL-10和IL-6 mRNA水平,ELISA检测血清抗体,以探讨程序性死亡受体-1(programmed cell death-1, PD-1)在疟原虫初次感染中对体液免疫应答的影响。结果发现,PD-1单抗阻断加速了P.b ANKA感染小鼠的死亡。与对照组相比,PD-1阻断组感染后第12天短寿浆细胞(CD138~+CD44~+)数量明显降低(P0.05),长寿浆细胞(CD138~+CD44~-、CD138~-CD44~+)和Tfh(CD4~+CXCR5~+)细胞数量无差异性改变,脾细胞IL-21的mRNA水平明显下降(P0.05),血清抗裂殖子表面蛋白(merozoite surface protein, MSP)-1特异性IgG无明显改变。P.b ANKA感染中PD-1通路可能通过影响Tfh分泌IL-21进而干扰浆细胞数量影响体液免疫应答。     

The role of Pvs28 in sporozoite development in Anopheles sinensis and its longevity in BALB/c mice

To develop a vivax malaria vaccine for blocking malarial transmission, the ookinete surface protein Pvs28 was cloned from Korean malaria patients using polymerase chain reaction. The Pvs28 gene consists of 726 bp and encodes 241 amino acids. It was subcloned into the expression vector pQE30 and expressed in Escherichia coli. The expressed recombinant protein, rPvs28, has a molecular weight of about 28 kDa in SDS–PAGE analysis. A monoclonal antibody against rPvs28 was produced using BALB/c mice. It inhibited sporozoite development in Anopheles sinensis mosquitoes (n = 81) which is one of the malaria vectors in Korea, with relatively high antibody titer against rPv28 persisting for more than 6 months. These results indicate that rPvs28 induces an immune response in mice that effectively blocks sporozoite development in mosquitoes. Therefore it could be a vaccine candidate for preventing vivax malaria in Korea.     

Enzymatic characterization of the Plasmodium vivax chitinase, a potential malaria transmission-blocking target

The chitinase (EC 3.2.1.14) of the human malaria parasite Plasmodium falciparum, PfCHT1, has been validated as a malaria transmission-blocking vaccine (TBV). The present study aimed to delineate functional characteristics of the P. vivax chitinase PvCHT1, whose primary structure differs from that of PfCHT1 by having proenzyme and chitin-binding domains. The recombinant protein rPvCHT1 expressed with a wheat germ cell-free system hydrolyzed 4-methylumbelliferone (4MU) derivatives of chitin oligosaccharides (β-1,4-poly-N-acetyl glucosamine (GlcNAc)). An anti-rPvCHT1 polyclonal antiserum reacted with in vitro-obtained P. vivax ookinetes in anterior cytoplasm, showing uneven patchy distribution. Enzymatic activity of rPvCHT1 shared the exclusive endochitinase property with parallelly expressed rPfCHT1 as demonstrated by a marked substrate preference for 4MU-GlcNAc₃ compared to shorter GlcNAc substrates. While rPvCHT1 was found to be sensitive to the general family-18 chitinase inhibitor, allosamidin, its pH (maximal in neutral environment) and temperature (max. at ~ 25 °C) activity profiles and sensitivity to allosamidin (IC₅₀ = 6 µM) were different from rPfCHT1. The results in this first report of functional rPvCHT1 synthesis indicate that the P. vivax chitinase is enzymatically close to long form Plasmodium chitinases represented by P. gallinaceum PgCHT1.     

Plasmodium vivax: Prevalence of mutations associated with sulfadoxine–pyrimethamine resistance in Plasmodium vivax clinical isolates from Pakistan

The main aim of the present study was to investigate the frequency of SNPs-haplotypes of dhfr and dhps genes associated to sulfadoxine–pyrimethamine (SP) resistance in Plasmodium vivax clinical isolates circulating in a malaria endemic area, Pakistan. All 164 collected isolates were analyzed for SNPs-haplotypes at positions 13, 33, 57, 58, 61, 117 and 173 of pvdhfr and 383 and 553 of pvdhps genes using PCR–RFLP methods. All examined isolates were found to carry wild-type amino acids at positions 13, 33, 57, 61 and 173, while 58R and 117N mutations were detected among 15.2% and 53.6% of isolates, respectively. Based on the size polymorphism of pvdhfr genes at repeat region, type B (79.3%) was the most prevalent variant. The combination of pvdhfr and pvdhps haplotypes demonstrated nine distinct haplotypes. The three most prevalent haplotypes were I₁₃P₃₃F₅₇S₅₈T₆₁S₁₁₇I₁₇₃/A₃₈₃A₅₅₃ (43.9%), I₁₃P₃₃F₅₇S₅₈T₆₁N₁₁₇I₁₇₃/A₃₈₃A₅₅₃ (33.6%) and I₁₃P₃₃F₅₇R₅₈T₆₁N₁₁₇I₁₇₃/A₃₈₃A₅₅₃ (12.2%). The presence of mutant haplotypes is worrying and indicates the emergence of drug tolerant/resistant P. vivax isolates in Pakistan in near future.